We build disease-awareness content that stays firmly on the right side of Schedule J, HCP-gated portals for the drug information that can't go public, and corporate/pharmacovigilance content — for a category where a content mistake can mean more than a ranking drop.
Figures from CDSCO's 2026 advisories, the Drugs and Magic Remedies Act, and global regulatory enforcement reporting — actual results depend on product category and starting content risk.
Schedule J of the Drugs and Cosmetics Rules lists 54 conditions — including diabetes, cancer, and infectious disease — where drug-claim advertising to the public is legally prohibited under the Drugs and Magic Remedies Act. CDSCO's March 2026 advisory on GLP-1 drugs made the enforcement posture explicit: no direct, surrogate, or influencer-led promotion that builds public brand recall for a prescription-only medicine, no matter how the message is framed. This isn't a soft guideline — violations carry criminal liability, up to a year's imprisonment.
That reshapes the entire content strategy. Public-facing content has to stay in disease-awareness territory — symptoms, risk factors, when to see a doctor — never naming or implying a specific drug's benefit. The drug-specific information HCPs actually need belongs behind credential-gated portals, doctor-only email programmes, and HCP-only applications, compliant with the Uniform Code for Pharmaceutical Marketing Practices. Off-label use can't be promoted through any channel, ever, even to physicians.
We build the two content tracks correctly separated from day one — disease-awareness SEO that's genuinely useful and genuinely compliant, and HCP-gated content architecture for everything that legally can't go public.
Everything a pharmaceutical company needs to build search visibility without crossing a legal line.
Content architecture that keeps public-facing pages firmly in disease-education territory — never naming or implying a specific drug's benefit for a Schedule J condition.
Credential-verified, doctor-only content architecture — the compliant channel for drug-specific information that can't be public.
A content review workflow built around current CDSCO advisories and the Drugs and Magic Remedies Act — catching risk before publication, not after an inquiry.
Manufacturing capability, GMP/Schedule M compliance status, and pipeline visibility for investors, partners, and regulators researching your company.
Findable, clear adverse-event reporting pathways and safety information — required by CDSCO's mandatory Pharmacovigilance Unit rules and genuinely useful for patients.
Bioequivalence, patent-status, and generic-availability content — relevant given India's position as the world's largest generic drug supplier.
Every page classified by Schedule J/DTC risk, HCP-gating status, and technical/content gaps identified.
Disease-awareness and HCP-gated content tracks planned and structurally separated.
Public and HCP-gated content produced with your medical/regulatory team's review built into the workflow.
Pipeline, compliance, and pharmacovigilance content published alongside the core programme.
Visibility, HCP engagement, and compliance risk tracked monthly with your department lead.
Transparent tiers. No lock-in contracts. Scale up as your product portfolio grows.
A full diagnostic before you commit to ongoing work.
Ongoing SEO for a single pharmaceutical brand or business unit.
Multi-brand pharmaceutical companies with several product lines.